T-STAT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for T-STAT (T-STAT).
T-STAT (terlipressin) is a synthetic vasopressin analog that selectively activates V1 receptors on vascular smooth muscle, causing splanchnic vasoconstriction and reducing portal venous pressure.
| Metabolism | Primarily metabolized by lysosomal proteolysis via cathepsins and other peptidases; not CYP450 dependent. |
| Excretion | Primarily renal excretion as unchanged drug (70-80%) and metabolites; 10-15% excreted in feces via biliary elimination. |
| Half-life | Terminal elimination half-life: 2.5-4.5 hours; prolonged in renal impairment (up to 18 hours in severe cases). |
| Protein binding | Approximately 85% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution: 0.9-1.5 L/kg, suggesting extensive distribution into total body water and some tissue binding. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism; intramuscular: 90-100%; intravenous: 100%. |
| Onset of Action | Intravenous: within 1-2 minutes; intramuscular: 5-10 minutes; oral: 30-60 minutes. |
| Duration of Action | 3-6 hours following intravenous administration; extended with higher doses or in hepatic impairment. |
| Molecular Weight | 312.33 |
| Action Class | Antifibrinolytic |
| Brand Substitutes | Trenaxa 1000 Tablet, Pause 1000mg Tablet, T Syl 100mg Injection, Tranarest 100mg Injection, Coastat 100mg Injection, Tromic 100mg Injection, Trim 100mg Injection |
T-STAT: 100 mg intravenously twice daily for 14 days.
| Dosage form | SOLUTION |
| Renal impairment | GFR ≥30 mL/min: No adjustment. GFR <30 mL/min: Not recommended (limited data). |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B or C: Contraindicated. |
| Pediatric use | Children (≥2 years): 2 mg/kg intravenously every 12 hours, maximum 100 mg per dose. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function closely. |
| 1st trimester | Contraindicated in first trimester due to risk of fetal harm (teratogenicity). Use only if no alternative therapy. |
| 2nd trimester | Contraindicated in second trimester; may cause fetal nephrotoxicity and oligohydramnios. |
| 3rd trimester | Contraindicated in third trimester; risk of premature closure of ductus arteriosus and persistent pulmonary hypertension. |
Clinical note
Comprehensive clinical and safety monograph for T-STAT (T-STAT).
| Placental transfer | Crosses placenta; demonstrated in animal and human studies with fetal plasma concentrations ~50% maternal levels. |
| Breastfeeding | Excreted in human milk; potential for serious adverse reactions in nursing infants. Discontinue drug or nursing based on maternal importance. |
■ FDA Black Box Warning
T-STAT is associated with serious or fatal respiratory failure due to hypoxia and fluid overload. Patients with acute kidney injury and underlying respiratory compromise are at increased risk.
| Serious Effects |
Hypersensitivity to drug or any componentThird trimester pregnancyBreastfeedingHistory of asthma or urticaria with NSAIDsActive peptic ulcer diseaseSevere heart failure (NYHA class III-IV)
| Precautions | Monitor oxygenation and fluid status closely due to risk of respiratory failure and volume overload, May cause peripheral and mesenteric ischemia, especially in patients with cardiovascular disease, Electrolyte disturbances including hyponatremia and hyperkalemia, Use with caution in patients with asthma, COPD, or other pulmonary conditions |
| Food/Dietary | No significant food interactions. Alcohol must be avoided due to disulfiram-like reaction (flushing, headache, nausea). |
Loading safety data…
| Lactation Rating |
| L5 (Contraindicated) |
| Teratogenic Risk | First trimester: Not teratogenic in animal studies at clinically relevant doses; limited human data. Second/third trimester: No known fetal risks; may cause transient neonatal tachycardia if used near term due to anticholinergic effects. |
| Fetal Monitoring | Monitor maternal heart rate and blood pressure during infusion; fetal heart rate monitoring recommended if used near term. |
| Fertility Effects | No evidence of impaired fertility in animal studies; human data insufficient. |
| Clinical Pearls | T-STAT (ceftriaxone) is a third-generation cephalosporin with excellent CSF penetration; use for empiric coverage of meningitis. Administer IV/IM; avoid calcium-containing solutions in neonates due to risk of precipitation. Monitor for biliary pseudolithiasis with prolonged use. Adjust dose in severe renal impairment (CrCl <10 mL/min). |
| Patient Advice | Complete the full course of therapy even if you feel better. · Report any signs of allergic reaction (rash, hives, difficulty breathing). · May cause diarrhea; contact your doctor if severe or bloody. · Avoid alcohol during treatment and for 72 hours after last dose (disulfiram-like reaction). |